Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
This study is a randomized, controlled trial to evaluate the efficacy and safety of the Omnipod® 5 System with the FreeStyle Libre 2 continuous glucose monitor compared to Multiple Daily Injections (MDI) along with the FreeStyle…
- Trial name
- RADIANT (NCT05923827)
- Testing
- Omnipod 5 System
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 189 people
- Sponsor
- Insulet Corporation
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Fit-One: A Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes
The Fit-One trial involves three prospective, randomized waitlist-controlled studies. These studies evaluate the effects of One Drop's digital therapeutics solution with and without Fitbit devices on the social cognitive…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, PreDiabetes
- Trial name
- Fit-One (NCT03459573)
- Testing
- One Drop | Experts On Track, One Drop | Experts On Call, One Drop | Experts Revive
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Chandra Osborn, PhD, MPH
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a…
- Trial name
- POLARIS (NCT06919354)
- Testing
- GNTI-122
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- GentiBio, Inc
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Compare Two Forms of LY2608204 in Healthy People
The purpose of this study is to compare 2 formulations of the study drug (LY2608204) in terms of how much gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01313286
- Testing
- LY2608204 Reference, LY2608204 Test
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
- Trial name
- NCT00135083
- Testing
- insulin glulisine
- Volunteers
- 347 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry
This study aims to evaluate the feasibility of non-invasive glucose monitoring by using photothermal deflectometry in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.
- Conditions
- Diabetes Mellitus Type 2, Diabetes Mellitus Type 1, Healthy
- Trial name
- NCT06088615
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Diamontech AG
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 1 Diabetes Mellitus
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)
The purpose of this study is to assess the long term safety and efficacy in subjects with Type 1 Diabetes Mellitus who completed the Protege Study (CP-MGA031-01).
- Trial name
- NCT00870818
- Testing
- Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- MacroGenics
Type 1 Diabetes Mellitus
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
- Trial name
- NCT04711226
- Testing
- AT-1501
- Where
- Canada
- Sponsor
- Anelixis Therapeutics, LLC
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Type1 Diabetes Mellitus
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and pharmacodynamics (PD) of multiple doses of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin…
- Trial name
- NCT03117998
- Testing
- REMD-477
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- REMD Biotherapeutics, Inc.
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients
The purpose of this study is to evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin
- Trial name
- NCT01055652
- Testing
- Dapagliflozin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
The purpose of this study is to measure how much of the study drug or insulin glargine gets into the blood stream and how long it takes the body to get rid of it. The effect of exercise will also be evaluated.
- Trial name
- NCT01784211
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace.
- Trial name
- NCT00229658
- Testing
- pramlintide acetate
- Where
- 107 sites in United States
- Volunteers
- 1,297 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and Europe. The aim of the trial is to compare the efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 (biphasic insulin aspart 30) in insulin naïve subjects with type 2…
- Trial name
- BOOST™ (NCT01513590)
- Testing
- insulin degludec/insulin aspart
- Where
- 49 sites in Algeria, Bulgaria and 8 more
- Volunteers
- 394 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss…
- Trial name
- NCT00570687
- Testing
- Technosphere Insulin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.